Nirav N. Desai is a director in Sterne Kessler’s Trial & Appellate and Electronics Practice Groups. Hespecializes in simplifying complex matters—inside the courtroom and out—and solving problems in theprocess. Nirav is experienced in a full range of intellectual property issues, with a particular focus onpatent litigation and counseling clients in global intellectual property strategy. An accomplished litigator,Nirav has served as lead counsel in district court litigation matters around the country and has beeninvolved in matters before district courts, appellate courts, the U.S. Patent and Trademark Office’s PatentTrial and Appeal Board (PTAB), and the U.S. International Trade Commission (USITC) in Section 337actions.
Nirav’s considerable experience in post-grant proceedings before the PTAB includes serving as leadcounsel and counsel in over 25 PTAB proceedings, representing clients, from innovative startups tobillion-dollar companies, in some of their toughest cases. In parallel district court and PTABproceedings, Nirav relies on his deep experience in both venues to craft a unified, cross-forum strategythat maximizes the strengths of each proceeding while mitigating the pitfalls.
Drawing on his interdisciplinary academic and legal training, Nirav has successfully represented companies of all sizes in both the high-tech and life sciences industries. From consumer products andsoftware to pharmaceuticals and medical devices, Nirav helps companies develop robust global IPstrategies that maximize return on IP investment. Recently Nirav has helped clients from all over theworld develop global IP protection and enforcement campaigns, including in the U.S., UK, India, theEuropean Union, the Nordics, and the Far East. Closer to home, Nirav has represented electronics,software, and consumer products companies in non-practicing entity and business-to-business patent,trademark, and licensing disputes in district court, the PTAB, and before the USITC.
In the life sciences arena, Nirav has litigated and counseled clients in the pharmaceutical, medicaldevices, and genetic diagnostics industries. An active ANDA litigator, he has represented genericpharma companies in Paragraph IV disputes involving blockbuster drugs, such as Abilify® (aripiprazole), Seroquel® (quetiapine fumarate), Daliresp® (roflumilast), Invokana® (canagliflozin), Jardiance® (empagliflozin), Staxyn® (vardenafil), and Brilinta® (ticagrelor) among others.
Further, Nirav is a trusted advisor to many clients providing counsel on patent portfolio development andlicensing in a wide range of industries, including artificial intelligence, digital healthcare, RFID and real-time locations systems, software applications, medical devices, and consumer products.
